When was Trivascular founded?

Trivascular was founded in 1998 and raised its 1st funding round 10 years after it was founded.

Where is Trivascular located?

Trivascular is headquartered in Santa Rosa, United States. It is registered at 2 Musick, Irvine, California 92618.

How many employees does Trivascular have?

As of Mar 31, 2026, the latest employee count at Trivascular is 43.

Is Trivascular a funded company?

Trivascular is a funded company, having raised a total of $261M across 8 funding rounds to date. The company's 1st funding round was a $***** Series C round, raised on Mar 31, 2008.

When was the latest funding round of Trivascular?

Trivascular's latest funding was a $***** Post IPO round on Aug 20, 2015, with participation from 0 investor.

What is the annual revenue of Trivascular?

Annual revenue of Trivascular is $31.8M as on Dec 31, 2014.

Where does Trivascular rank among its competitors?

Trivascular ranks 2nd amongst 30 active competitors, of which 4 are funded. It stands 1st in terms of total funding among its competitors. The most recent competitor to raise funding was Endoron Medical, which secured $10M in Jul, 2024.

Who are the top competitors of Trivascular?

Trivascular's top competitors include Endologix, Myval and Jotec. Among them, Endoron Medical secured the most recent funding round in July, 2024.

Trivascular - 2026 Company Profile, Team, Funding, Competitors & Financials

Trivascular is a public company based in Santa Rosa (United States), founded in 1998 by Joseph Humphrey and Michael Chobotov. It operates as a Designs and manufactures for endovascular aortic repair equipment. Trivascular has raised $261M in funding from Kaiser Permanente Ventures. The company has 30 active competitors, including 4 funded and 10 that have exited. Its top competitors include companies like Endologix, Myval and Jotec.

Company Details

TriVascular is a company that designs and manufactures endovascular aortic repair equipment. It offers Ovation Abdominal Stent Graft System that assists in profiling of endovascular graft for the treatment of abdominal aortic aneurysms. The system is FDA-approved.

Website: www.trivascular.com
Social
Email ID: *****@trivascular.com
Phone Number: +1 **********
Registered Address: 2 Musick, Irvine, California 92618

Key Metrics

Founded Year

1998

Location

Santa Rosa, United States

Stage

Public

Total Funding

$261M in 8 rounds

Latest Funding Round

Post IPO, Aug 20, 2015, $*****

Investors

Kaiser Permanente Ventures & 7 more

Ranked

2^nd among 30 active competitors

Annual Revenue

$31.8M as on Dec 31, 2014

Employee Count

43 as on Mar 31, 2026

Similar Companies

Endologix & 32 more

Exit Details

Public

View Trivascular's full profile

Trivascular is associated with 2 legal entities given below:

Legal Entity Name	Date of Incorporation	Revenue	Latest Employee Count	Documents
ENDOLOGIX LLC CIN: 68-0328265 , United States, Active	Dec 31, 1997	-	488 (As on Dec 31, 2019)	-
TRIVASCULAR TECHNOLOGIES, INC. CIN: 1432732 , United States, Active	Jul 10, 2007	$31.8M (As on Dec 31, 2014)	307 (As on Dec 31, 2014)	-

Trivascular got listed on Apr 15, 2014.

Click here to take a look at Trivascular's IPO in detail

Trivascular has raised a total funding of $261M over 8 rounds. Its first funding round was on Mar 31, 2008. Trivascular has 7 institutional investors and 1 angel investor.

Here is the list of recent funding rounds of Trivascular:

Filter this list

Date of Funding	Funding Amount	Round Name	Post-Money Valuation	Revenue Multiple	Lead Investors	Other Investors
Aug 20, 2015	3413850	Post IPO	9930271	6813298	9051152	1217655
Dec 12, 2013	4661784	Series D	3241279	1659912	6082464	6048107
Nov 18, 2013	6989290	Series D	8890531	8460227	9585018	New Enterprise Associates

Access funding benchmarks and valuations. Sign up today!

View details of Trivascular's funding rounds and investors

The founders of Trivascular are Joseph Humphrey and Michael Chobotov.

Here are the details of Trivascular's key team members:

Joseph Humphrey: Co-Founder of Trivascular.
Contact Info: 1 email address
Michael Chobotov: Chief Technology Officer, Board of Directors, Co-founder of Trivascular.

View details of Trivascular's Founder profiles and Board Members

Trivascular's employee count trend

Trivascular has 43 employees as of Mar 26. Here is Trivascular's employee count trend over the years:

Uncover Trivascular's growth story! Sign up today!

Access Tracxn on any website

Our Google Chrome extension lets you view company details while browsing their websites

Install Tracxn Extension

Top competitors of Trivascular include Endologix, Myval and Jotec. Here is the list of Top 10 competitors of Trivascular, ranked by Tracxn score:

Rank	Company Details	Short Description	Total Funding	Investors	Tracxn Score
1st	Endologix 1992, Irvine (United States), Public	Minimally invasive treatments for aortic disorders	-	MPM Capital, Deerfield & 4 others	55/100
2nd	Trivascular 1998, Santa Rosa (United States), Public	Designs and manufactures for endovascular aortic repair equipment	$261M	Redmile Group, Pinnacle Ventures & 6 others	53/100
3rd	Myval 1998, Vapi (India), Unfunded	Provider of transcatheter aortic heart valve replacement system	-	-	45/100
4th	Jotec 2000, Hechingen (Germany), Acquired	Stents and Grafts for Aortic and Peripheral arterial disease	-	-	41/100
5th	Endoron Medical 2019, Kfar Saba (Israel), Series A	Manufacturer of endovascular suture-like device for cardiovascular treatment	$15M	Sofinnova Partners, MD Start & 2 others	40/100
6th	Aptus Endosystems 2002, Sunnyvale (United States), Acquired	Device for endovascular aortic aneurysm repair	$70M	Longitude Capital, USVP & 7 others	39/100
7th	Medeon Biodesign 2012, Taipei (Taiwan), Public	Developer of minimally invasive devices in the field of cardiovascular and laparoscopy	-	YFY, Helicase Venture	39/100
8th	Embolic Protection System 2013, Kalamazoo (United States), Series C	Embolic protection system designed for whole-body protection during left heart procedures	$19.8M	-	37/100
9th	Altura Medical 2008, Menlo Park (United States), Acquired	Endovascular devices for aortic aneurysms	$49.5M	New Leaf Venture Partners, Advanced Technology Ventures ... & 1 others	36/100
10th	Remon Medical 1997, Caesarea (Israel), Acquired	Miniature implants to monitor intra-aneurysm pressure	$26M	Polaris Partners, KBL & 6 others	34/100